Compare · IVVD vs NVAX
IVVD vs NVAX
Side-by-side comparison of Invivyd Inc. (IVVD) and Novavax Inc. (NVAX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IVVD and NVAX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- NVAX is the larger of the two at $1.31B, about 9.4x IVVD ($139.7M).
- NVAX has been more active in the news (8 items in the past 4 weeks vs 4 for IVVD).
- NVAX has more recent analyst coverage (21 ratings vs 7 for IVVD).
- Company
- Invivyd Inc.
- Novavax Inc.
- Price
- -
- -
- Market cap
- $139.7M
- $1.31B
- 1M return
- -26.73%
- -
- 1Y return
- -81.34%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 4
- 8
- Recent ratings
- 7
- 21
Novavax Inc.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Latest IVVD
- SEC Form 10-Q filed by Invivyd Inc.
- Invivyd Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
- Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Invivyd Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
- Invivyd to Participate in Upcoming September Investor Conferences
Latest NVAX
- Novavax to Participate in Jefferies London Healthcare Conference
- SEC Form SCHEDULE 13G filed by Novavax Inc.
- SEC Form 10-Q filed by Novavax Inc.
- Novavax Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights
- SEC Form 8-K filed by Novavax Inc.
- Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
- Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026
- Amendment: SEC Form SCHEDULE 13D/A filed by Novavax Inc.
- Novavax to Participate in September Investor Conferences